The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the neurocognitive effects of these drugs. The present study compared the effects of risperidone and haloperidol on secondary memory in a group of treatment-resistant schizophrenia patients. The study design included a baseline phase and two double-blind phases in which patients were randomly assigned to medication under two different dose conditions (fixed dose and flexible dose). Secondary memory was assessed at baseline, fixed-dose, and flexible-dose phases, using the California Verbal Learning Test (CVLT). Six measures were selected, which formed three factors (general verbal learning ability, retention, and learning strategy). Risperidone-treated patients showed greater improvement than haloperidol-treated patients in general verbal learning ability, a finding characterized by significant treatment effects on CVLT measures of learning acquisition, recall consistency, and recognition memory. After controlling for benztropine status, differences on the measures of learning acquisition and recall consistency remained significant, and differences in recognition memory weakened slightly (p = 0.07). No significant treatment effects were noted on retention or learning strategy. These findings suggest that risperidone may exert a facilitating effec^onjhe acquisition of new verbal information, an effect that does not appear to be due to the activation of semantic encoding strategies.
Among all domains of neurocognitive functioning, deficits affecting learning and memory may have the greatest impact on daily functioning. Memory deficits have been well studied in patients with schizophrenia (Koh et al. 1973; Koh and Kayton 1974; Calev et al. 1983 Calev et al. , 1987 Gold et al. 1992) , with some evidence suggesting that the level of impairment in this domain may be more severe than that noted in other neurocognitive areas (Saykin et al. 1991 ). In addition, several studies have reported that memory functioning is a strong predictor of short-and long-term functional outcome in areas such as skill acquisition, social problem solving, and community outcome (Mueser et al. 1991; Kern et al. 1992; Goldman et al. 1993; Bellack et al. 1994; Buchanan et al. 1994; Conigan et al. 1994a Conigan et al. , 1994 Green 1996) . Given that memory functioning may be disproportionately affected in schizophrenia and that, among neurocognitive constructs, it appears to be a highly reliable predictor and correlate of functional outcome, this area appears to be a logical target for pharmacological intervention.
Most theories about the processing stages of memory include a three-stage or elaborated two-stage model (Atkinson and Shiffrin 1968; Thompson 1988; Wickelgren 1981) . The stages include registration or sensory memory, primary or immediate memory, and secondary or long-term memory. This study considers only the third stage. Secondary memory refers to the ability to store information over time and is typically assessed using measures of list learning, paired-associate learning, or recall of short story material. The ability to store information over time is intimately tied to processes of learning and consolidation, the former referring to the acquisition of new information and the latter to the storing-of information as long-term memory. Learning and consolidation are closely linked in that, by definition, learning requires consolidation.
The effects of antipsychotic treatment on memory functioning are not well understood. A review of studies examining the effects of conventional neuroleptics on memory fails to provide much evidence for a therapeutic effect (Medalia et al. 1988; Cassens et al. 1990; Gold et al. 1991) . The findings generally indicate no effect of short-term (4-8 weeks) or long-term (> 8 weeks) neuroleptic administration on memory tasks involving recall of short stories or paired-associate learning. In addition, it appears that the anticholinergic activity inherent in conventional neuroleptics (Bassuk and Schoonover 1983) , as well as the anticholinergic activity from antiparkinsonian medication frequently used in conjunction with conventional neuroleptics, may actually impair verbal memory (Tune et al. 1982; Perlick et al. 1986 ).
The introduction of atypical antipsychotic medications has been accompanied by a growing interest in the neurocognitive effects of these drugs. A few studies have examined the effects of clozapine on memory functioning; however, the results are unclear. Haggar et al. (1993) examined the effects of open-label clozapine on neurocognition in a sample of schizophrenia patients (n -36) using a broad-based battery that included measures of secondary memory. Neurocognitive assessments were conducted at baseline, 6 weeks, and 6 months after initiation of treatment. Improvement was noted in immediate recall of a list-learning measure between baseline and the 6-month assessment, but not between baseline and the 6-week assessment. In another study (Goldberg et al. 1993 ), a sample of psychotic patients (n = 15) was initially assessed while on a conventional neuroleptic and then retested after conversion to clozapine (range 3-24 months; mean = 15 months). No significant improvement from baseline was noted on any of the verbal memory measures, and visual memory actually declined. Hoff et al. (1996) tested a small sample of State-hospitalized schizophrenia patients (n -20) on a battery of neurocognitive tests at baseline, when patients were maintained on a conventional neuroleptic, and after 12 weeks on clozapine treatment. No significant differences were noted between the two test occasions on any of the measures of secondary memory, which included short story recall, paired-associate learning, and a learning acquisition score from the California Verbal Learning Test (CVLT; Delis et al. 1987) . Consistent with the findings of Goldberg et al. (1993) , Hoff et al. (1996) also found a significant decline in visual memory associated with clozapine treatment. The only double-blind study to examine the effects of clozapine on secondary verbal memory (Buchanan et al. 1994 ) compared the effects of clozapine versus haloperidol treatment at baseline and at the end of a 10-week drug treatment period. No significant effect of drug treatment was noted on the measures of short story recall or pairedassociate learning. Following completion of the 10-week double-blind trial, subjects were converted to or maintained on clozapine treatment and then followed for 1 year on open-label clozapine. The 1-year followup assessment indicated a trend for improvement on short story recall, but indicated no other effects on verbal memory.
The effects of risperidone, a new agent with a pattern of binding affinity different than that of clozapine, are largely unexplored. A double-blind study conducted by our lab reported a beneficial effect on verbal working memory for risperidone, compared with haloperidol (Green et al. 1997) . In that study, treatment-resistant schizophrenia patients were administered a measure of a component of verbal working memory (articulatory loop) at baseline and at the end of fixed-dose and flexible-dose double-blind phases. Risperidone-treated patients showed a greater improvement from baseline than haloperidoltreated patients. The improvement in performance was maintained over the fixed-and flexible-dose phases of the study.
Working memory involves a neuroanatomical network that is separate from but overlaps the one involved in secondary memory. Several studies have pointed to the dorsolateral prefrontal cortex of the brain, with its projections to sensory, limbic, and motor systems, as primary to working memory (Goldman-Rakic 1987) . On the other hand, neural structures involved in secondary memory include the rhinal cortex, hippocampus, amygdala, and prefrontal cortex (Petri and Mishkin 1994) . Given the differences in neural circuitry associated with working versus secondary memory, it is difficult to predict whether Green et al.'s (1997) findings on working memory may extend to secondary memory processes.
The present study used a double-blind study design to compare the effects of haloperidol versus risperidone on a widely used measure of secondary memory, the CVLT, in a group of treatment-resistant schizophrenia patients. The CVLT provides a comprehensive measurement of learning and memory abilities, and includes specific measures designed to assess the encoding, storage, and retrieval of verbal information. The CVLT allows us to examine whether atypical agents affect selected aspects of learning and memory and whether changes in performance are related to the increased use of an organizing strategy (i.e., semantic clustering). The use of an organizational strategy may indicate the activation of frontal mechanisms. Hence, the goals of the present study are twofold: (1) to test whether risperidone treatment is associated with improvement in memory compared with haloperidol treatment, and (2) if so, to determine whether improvement in memory functioning was accompanied by changes in the use of organizing strategies.
Method
Subjects. The present sample was drawn from a clinical trials study described in a previous report (Green et al. 1997) . Briefly, subjects were recruited from Camarillo State Hospital and the West Los Angeles Veterans Affairs Medical Center, and included 64 patients who met criteria for schizophrenia based on the Structured Clinical Interview for DSM-III-R (Spitzer et al. 1990 ). All interviewers were trained by the Diagnosis and Psychopathology Unit of the UCLA Center for Research on Treatment and Rehabilitation of Psychoses (R.P. Liberman, director) and attained a minimum kappa of 0.75 for rating the presence of psychotic and mood items. All patients met criteria for treatment-resistant schizophrenia according to the criteria of Kane et al. (1988) . In addition, all patients met symptom severity and selection criteria at the time of initial screening (see Green et al. 1997 for full selection criteria). Table 1 presents the demographic characteristics, chronicity, and psychiatric symptom ratings for the sample, divided according to treatment group (haloperidol or risperidone). Written informed consent was obtained from all patients who participated in the study and, when a conservator was assigned, from the conservator as well.
At the Camarillo site, the study design consisted of a baseline phase, a brief period of placebo washout, and two double-blind phases. During baseline, the majority of patients were maintained on 20 mg/day (range 15-30 mg/day) of haloperidol over the 3-week baseline (stabilization) period. During placebo washout, patients received placebo medication for a period of 3 to 7 days. For the first 4-week double-blind phase (fixed-dose), patients were randomly assigned to receive either 6 mg/day of risperidone or 15 mg/day of haloperidol. For the second double-blind phase (flexible-dose), patients' medication dosage could be adjusted at the discretion of the treating psychiatrist. Following participation in the study, all patients who had been assigned to haloperidol were offered a trial on open-label risperidone. The study design was identical at the VA site, except that the baseline period consisted of an off-medication, lead-in phase from which patients moved directly to the fixed-dose phase. The differences in study design at the two sites may increase the variability in scores obtained at baseline, but they should not impose a systematic bias on treatment effects because subjects were randomly assigned to risperidone or haloperidol treatment within each site.
During the period of the study protocol, patients were administered lorazepam or chloral hydrate as needed, but no other psychoactive medications. For those patients who received lorazepam, testing was not initiated until at least 10 hours after dose administration. Benztropine 
Semantic clustering ratio:
The ratio of observed to expected correct semantic clustering scores from recall of items on List A, Trials 1-5. For the observed semantic clustering score, one point is awarded whenever a subject recalls a List A item immediately after another List A item from the same semantic category. Expected semantic clustering scores indicate chance performance and are determined by the subject's total number of items recalled and the number of categories represented for a particular trial. A semantic clustering ratio equal to 1 indicates chance clustering. 5. Recall consistency: The percentage of items correctly recalled on one of the first four learning trials of List A that are also correctly recalled on the immediately succeeding trial. It is calculated by the formula: ((number of times a correct item from List A, Trials 1-4 was correctly recalled on the next trial)/(List A, Trials 1-4 total recall)) X 100. 6. Total intrusions: The total number of items reported during the free and cued recall trials that were not a member of List A. All dependent measures were derived in accordance with the CVLT manual except for the retention measure, in which we considered the amount of information lost, as opposed to retained, and used the single best learning trial, instead of Trial 5, as the marker of peak learning. The best trial was used because of variability in recall scores obtained over the five learning trials.
BPRS. Assessment of psychiatric symptoms was measured using the 24-item BPRS (Ventura et al. 1993) . The BPRS was administered by interviewers who were trained to a minimum intraclass correlation coefficient of 0.80 by the Diagnosis and Psychopathology Unit. Two measures were drawn from the BPRS for use as covariates in the statistical analyses: a measure of change in positive symptoms from baseline and a measure of change in negative symptoms from baseline. The measure for positive symptoms was the Thinking Disturbance subscale score, which was calculated by summing the ratings for the BPRS items of hallucinations, unusual thought content, and conceptual disorganization. The measure for negative symptoms was the Withdrawal/Retardation subscale score, which was calculated by summing the ratings for the BPRS items of blunted affect, emotional withdrawal, and motor retardation.
Statistical Analyses. Initially, we performed contrasts on the measures of demographic characteristics, symptom ratings, and chronicity to examine possible group differences at baseline.
Because the six dependent measures do not necessarily indicate six distinct neurocognitive constructs, we conducted a factor analysis of the baseline performance data using a principal components procedure. These data were further subjected to a varimax rotation procedure. Factors yielding eigenvalues greater than 1.0 were retained. The factor loadings from the varimax rotation of the baseline data were then used to derive factor scores for the CVLT data from the double-blind treatment phases. Data from each of the derived factor scores were then analyzed using a 2 X 2 analysis of covariance (ANCOVA). The between-subjects variable was drug assignment (haloperidol versus risperidone), and the repeated-measures within-subjects variable was drug phase (fixed versus flexible). Baseline factor scores were used as a covariate. All data were analyzed using a mixed-model procedure that uses maximum probability likelihood to estimate the parameters of the analysis of variance (ANOVA) and does not require complete cases.
To see which variables of the factors were affected most, we then analyzed data from each of the six CVLT measures separately, using a 2 X 2 repeated-measures ANCOVA for each analysis. Three sets of analyses were conducted for each variable. The analyses differed according to the entry of covariates. Initially, the data were analyzed using only baseline scores as a covariate. Then, to control for possible indirect effects of anticholinergic medication on performance, a second series of analyses was conducted using the additional (time varying) covariate of benztropine status (receiving versus not receiving) at the fixed-and flexible-dose phases. The third series of analyses included change in positive and change in negative symptoms from baseline as additional covariates to examine the degree to which memory changes were independent of changes in psychiatric symptoms.
Results
There were no differences between the two groups on any demographic or chronicity measures, and the two groups were also comparable in terms of their level of symptom severity at baseline (see table 1 ).
The results of the varimax rotation yielded a threefactor solution. The factors represent general verbal learning ability, retention, and learning strategy. Table 2 shows the varimax rotated factor structure matrix for the CVLT data obtained at baseline for the entire sample. The score for total recall loaded heaviest on the first factor (general verbal learning ability), along with scores for recall consistency, total intrusions, and the discriminability index (all factor loadings > 0.70). The derived retention score (0.91) loaded almost entirely on the second factor. Similarly, the semantic clustering ratio (0.96) loaded primarily on the third factor.
When we examined treatment effects on the three factors with baseline performance entered as a covariate, we found a significant effect of group on the first factor (general verbal learning ability; F (1,43) = 4.70; p = 0.036), but not the other two. There was no effect of phase and there was no group X phase interaction for any of the three derived factor scores.
We next analyzed each of the CVLT measures separately. When analyzed with only baseline scores included as a covariate, significant group effects were found for the factor one variables of learning acquisition (F (1,56) = 6.21, p = 0.016), recognition memory (F (1,56) = 5.38, p = 0.024), and recall consistency (F (1,56) = 9.05, p = 0.004). The findings for learning acquisition and recognition memory are illustrated in figures 1 and 2, respectively.
A trend favoring a beneficial effect for risperidone was noted on the factor two variable of retention (F (1,56) = 3.26, p = 0.076). The groups did not differ on the factor three variable of semantic clustering. There were no significant group X phase interactions on any of the dependent measures. There was one significant effect of phase: both groups showed improvement in their retention of items from the fixed-to flexible-dose phase (F (1,49) = 6.62, p = 0.013). This improvement is most likely due to practice effects from repeated administration of the same version of the CVLT. Table 3 presents the two groups' means and standard deviations for the factor one variables of general verbal learning ability (learning acquisition, recall consistency, total intrusions, and recognition), and table 4 presents the two groups' means and standard deviations for the derived retention score and the semantic clustering ratio. When the time-varying covariate of benztropine status was entered into the analyses, the effect of group remained significant for learning acquisition (p = 0.013) and recall consistency (p = 0.023); the significant group effect for recognition memory weakened slightly (p = 0.073). The trend for retention became nonsignificant.
When the additional time-varying covariates of change in positive and change in negative symptoms were then entered into the analyses, the effect of group remained significant for learning acquisition (p -0.045), and the p value for recall consistency became a trend (p = 0.073).
Discussion
Patients receiving risperidone showed significantly greater improvement than haloperidol-treated patients in general verbal learning ability. Greater gains were noted on measures of learning acquisition, recall consistency, and recognition. The magnitude of the improvement was not trivial. Learning acquisition for risperidone-treated patients increased nearly a full standard deviation (SD) from baseline performance levels. By comparison, haloperidol-treated patients showed roughly a 0.25 SD increase from baseline. Despite the significant improvement in learning acquisition for risperidone-treated patients, their performance on these variables was not normalized. Using means and SDs from a normative sample (Delis et al. 1987) , the performance of the risperidone group went from about 4 SDs below normal at baseline to about 2 SDs below normal during the double-blind phase.
Patients in the haloperidol group received anticholinergic medication at rates two to three times that of the risperidone-treated patients. When we controlled for the effects of benztropine status on performance, the results for learning acquisition and recall consistency remained significant and the findings for recognition weakened only slightly. Hence, the significant differences between groups on these components of general verbal learning ability are not easily explained by the anticholinergic effects of benztropine. When changes in positive and negative symptoms were entered into the statistical analyses along with benztropine status and baseline performance, the findings for learning acquisition remained significant, the findings for recall consistency weakened slightly (p = 0.07), and the findings for recognition memory became nonsignificant. Although controlling for changes in symptoms did not substantially alter the findings, it should be noted that changes in positive symptoms showed a relationship to performance on the CVLT. As positive symptoms decreased, memory performance increased on some indices (learning acquisition, r = -0.48; p < 0.001; recall consistency, r = -0.39; p < 0.01; and recognition memory, r = -0.41; p < 0.001). Changes in negative symptoms were unrelated to performance on any of the selected memory measures.
Interpretation of changes in psychiatric symptoms vis-a-vis changes in neurocognition is not straightforward. It is possible that changes in psychiatric symptoms propel changes in certain areas of neurocognition (Mortimer 1997) . However, it is entirely possible that the opposite is true, that changes in neurocognition drive the changes in psychiatric symptoms. If psychiatric symptom changes are the result of alterations in basic neurocognition, we could consider the medications to have direct neurocognitive effects and indirect symptom effects. At this time we can only refer to the degree of independence of the two types of medication effects without making causal inferences.
Risperidone's influence on secondary memory may involve its action at the 5-HT 2 receptor. Improvement in learning and memory may be associated with serotonergic antagonism, although the literature is not at all definitive (Keefe et al. 1999, this issue) . In animals, 5-HT antagonists have been shown to improve certain aspects of memory (e.g., aversive memory), while 5-HT agonists have been shown to impair it (McEntee and Crook 1991). Some evidence indicates that the improvements in memory may be specifically related to involvement of the 5-HT 2 receptor subtype. Strek et al. (1989) reported that among the 5-HT blockers they tested, only those with a selective affinity for 5-HT 2 receptors were effective at preventing memory disturbances.
One notable finding from the current study is that the rather substantial improvement in learning did not appear to be related to changes in the use of semantic organization strategies. Both groups were very consistent across study phases on the semantic clustering index. Normal adults typically show a preference for organizing items from the CVLT according to the four taxonomic categories (i.e., fruits, tools, spices and herbs, and clothing), but schizophrenia patients generally do not (Paulsen et al. 1995 ). It appears that risperidone improves memory functioning through some mechanism independent of semantic organization, perhaps via an alternative organizational strategy (e.g., phonemic encoding) or through a boost in memory capacity.
This article reports on one step in a program of research from our laboratory that examines the neurocognitive effects of risperidone versus haloperidol in treatment-resistant schizophrenia. In exploring this question, we have intentionally adopted an approach typically used in experimental psychology, in which neurocognitive constructs are systematically examined separately. We chose this approach over the more typical approach of examining a broad battery of neuropsychological measures because we believe that the field will benefit from a sequence of thorough examinations of well-identified constructs with appropriate control of covariates. This intensive approach is considerably more informative than the extensive battery approach for understanding medication effects on any given construct. A limitation of this approach is that the pattern of medication effects across different constructs emerges over time and is not immediately apparent.
As noted by Green and Nuechterlein (1999, this issue) , the time may be ripe to develop effective pharmacological treatments that target not only symptoms of psychotic disorders, but more functionally relevant neurocognitive processes as well. It is not known what improvements in learning and memory on a test such as the CVLT mean in terms of daily functioning, but given the strong predictive value of secondary memory to multiple aspects of functional outcome, this is a logical area for followup investigation. Certainly, the magnitude of impairment that remains, even after improvement resulting from risperidone treatment, illustrates the need for more effective pharmacological agents and adjunctive cognitive-behavioral interventions to treat the neurocognitive deficits associated with schizophrenia. The current study was designed to address a prerequisite question of whether learning and memory can be altered with new antipsychotic agents. If we become convinced that new agents improve memory in individuals with schizophrenia, other logical followup questions will concern the neurochemical mechanism of the effect. Findings from both human and animal studies may ultimately help isolate the desirable receptor binding properties for future pharmacological treatments in this area.
